GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dimerix Ltd (ASX:DXB) » Definitions » Total Liabilities

Dimerix (ASX:DXB) Total Liabilities : A$13.37 Mil (As of Dec. 2023)


View and export this data going back to 1993. Start your Free Trial

What is Dimerix Total Liabilities?

Dimerix's Total Liabilities for the quarter that ended in Dec. 2023 was A$13.37 Mil.

Dimerix's quarterly Total Liabilities increased from Dec. 2022 (A$1.50 Mil) to Jun. 2023 (A$11.79 Mil) and increased from Jun. 2023 (A$11.79 Mil) to Dec. 2023 (A$13.37 Mil).

Dimerix's annual Total Liabilities declined from Jun. 2021 (A$7.95 Mil) to Jun. 2022 (A$2.07 Mil) but then increased from Jun. 2022 (A$2.07 Mil) to Jun. 2023 (A$11.79 Mil).


Dimerix Total Liabilities Historical Data

The historical data trend for Dimerix's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dimerix Total Liabilities Chart

Dimerix Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.74 2.63 7.95 2.07 11.79

Dimerix Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.12 2.07 1.50 11.79 13.37

Dimerix Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Dimerix's Total Liabilities for the fiscal year that ended in Jun. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=11.756+(0+2.5673907444457E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0.038)
=11.79

Total Liabilities=Total Assets (A: Jun. 2023 )-Total Equity (A: Jun. 2023 )
=17.758-5.963
=11.80

Dimerix's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=3.113+(0+10.26
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=13.37

Total Liabilities=Total Assets (Q: Dec. 2023 )-Total Equity (Q: Dec. 2023 )
=15.089-1.717
=13.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dimerix Total Liabilities Related Terms

Thank you for viewing the detailed overview of Dimerix's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Dimerix (ASX:DXB) Business Description

Traded in Other Exchanges
N/A
Address
425 Smith Street, Fitzroy, VIC, AUS, 3065
Dimerix Ltd is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs. The company is developing five product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for COVID-19 pneumonia patients in ICU; DMX-200 for respiratory complications in Covid-19 patients; and DMX-700 for COPD; as well as the proprietary ReceptorHIT assay technology.

Dimerix (ASX:DXB) Headlines

No Headlines